MLYS - Mineralys Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.00
DETAILS
HIGH:
$56.00
LOW:
$30.00
MEDIAN:
$52.00
CONSENSUS:
$46.00
UPSIDE:
54.10%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||||
| R&D Expenses | 132.0 | 168.6 | 70.4 | 26.2 | 16.3 | 2.4 |
| SG&A Expenses | 38.6 | 23.8 | 14.3 | 5.2 | 2.4 | 0.5 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 170.6 | 192.4 | 84.7 | 31.5 | 18.7 | 2.9 |
| Operating Income | ||||||
| Operating Income | (170.6) | (192.4) | (84.7) | (31.5) | (18.7) | (2.9) |
| Interest Expense | 0 | 0 | 0 | 1.7 | 0.0 | 0.1 |
| Interest Income | 16.0 | 14.6 | 12.8 | 1.7 | 0 | 0 |
| Profitability | ||||||
| EBITDA | (170.5) | (192.4) | (84.7) | (31.5) | (19.4) | (3.3) |
| EBIT | (170.6) | (192.4) | (84.7) | (31.5) | (19.4) | (3.3) |
| Income Before Tax | (154.7) | (177.8) | (71.9) | (29.8) | (19.4) | (3.4) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (154.7) | (177.8) | (71.9) | (29.8) | (19.4) | (3.4) |
| Per Share Data | ||||||
| EPS (Basic) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Shares Outstanding | 67.7 | 48.5 | 36.2 | 5.2 | 5.0 | 4.6 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Current Assets | ||||||
| Cash & Cash Equivalents | 172.9 | 114.1 | 49.3 | 87.7 | 10.6 | 1.4 |
| Short-Term Investments | 483.7 | 84.1 | 187.3 | 22.4 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 4.8 | 7.2 | 12.5 | 2.7 | 0 | 0 |
| Total Current Assets | 661.4 | 205.4 | 249.1 | 112.8 | 11.1 | 1.5 |
| Non-Current Assets | ||||||
| Property, Plant & Equipment | 0.0 | 0.1 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 2.5 | 0 | 0 | 0 |
| Other Non-Current Assets | 0.4 | 0.5 | 0.1 | 1.6 | 0.0 | 0.0 |
| Total Non-Current Assets | 0.4 | 0.6 | 2.5 | 1.6 | 0.0 | 0.0 |
| Total Assets | 661.8 | 205.9 | 251.6 | 114.4 | 11.1 | 1.5 |
| Current Liabilities | ||||||
| Account Payables | 2.0 | 0.5 | 0.6 | 1.9 | 0.8 | 0.5 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 4.5 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.6 | 0 | 1.6 | 0.7 | 0.3 | 0 |
| Total Current Liabilities | 15.1 | 14.6 | 10.5 | 8.1 | 5.1 | 5.1 |
| Non-Current Liabilities | ||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 158.6 | 29.0 | 0 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 158.6 | 29.0 | 0 |
| Total Liabilities | 15.1 | 14.6 | 10.5 | 166.7 | 34.0 | 5.1 |
| Stockholders' Equity | ||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (457.2) | (302.5) | (124.7) | (52.8) | (23.0) | (3.6) |
| Accumulated Other Comprehensive Income | 0 | 0 | (251.6) | 0 | 0 | 0 |
| Total Stockholders' Equity | 646.7 | 191.3 | 241.2 | (52.3) | (22.9) | (3.6) |
| Total Liabilities & Equity | 661.8 | 205.9 | 251.6 | 114.4 | 11.1 | 1.5 |
| Debt Metrics | ||||||
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.5 |
| Net Debt | (172.9) | (114.1) | (49.3) | (87.7) | (10.6) | 3.1 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | (154.7) | (177.8) | (71.9) | (29.8) | (19.4) | (3.4) |
| Depreciation & Amortization | 0.1 | 0.0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.3 | 11.3 | 5.1 | 0.5 | 0.1 | 0.0 |
| Change in Working Capital | 2.7 | 9.5 | (7.5) | 0.8 | 4.1 | 0.5 |
| Other Non-Cash Items | (9.9) | (9.4) | (6.9) | (0.6) | 0.7 | 0.5 |
| Operating Cash Flow | (142.4) | (166.3) | (81.2) | (29.2) | (14.6) | (2.5) |
| Investing Activities | ||||||
| Capital Expenditure | (0.0) | (0.1) | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (814.7) | (373.4) | (348.0) | (71.8) | 0 | 0 |
| Sales/Maturities of Investments | 425 | 488.5 | 187.5 | 50 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (389.8) | 115.0 | (160.5) | (21.8) | 0 | 0 |
| Financing Activities | ||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 3.9 |
| Stock Repurchased | 0 | 0 | 0 | (1.6) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0.1 | 0.3 | 0 | 0 | 0 |
| Financing Cash Flow | 591.0 | 116.1 | 203.2 | 128.0 | 23.8 | 3.8 |
| Cash Position | ||||||
| Net Change in Cash | 58.8 | 64.8 | (38.4) | 77.0 | 9.3 | 1.4 |
| Cash at Beginning | 114.1 | 49.3 | 87.7 | 10.7 | 1.4 | 0 |
| Cash at End | 172.9 | 114.1 | 49.3 | 87.7 | 10.7 | 1.4 |
| Free Cash Flow | (142.4) | (166.4) | (81.2) | (29.2) | (14.6) | (2.5) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | (170.6) | (192.4) | (84.7) | (31.5) | (18.7) | (2.9) |
| Net Income | (154.7) | (177.8) | (71.9) | (29.8) | (19.4) | (3.4) |
| EPS (Diluted) | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Balance Sheet | ||||||
| Cash & Equivalents | 172.9 | 114.1 | 49.3 | 87.7 | 10.6 | 1.4 |
| Total Assets | 661.8 | 205.9 | 251.6 | 114.4 | 11.1 | 1.5 |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.5 |
| Stockholders' Equity | 646.7 | 191.3 | 241.2 | (52.3) | (22.9) | (3.6) |
| Cash Flow | ||||||
| Operating Cash Flow | (142.4) | (166.3) | (81.2) | (29.2) | (14.6) | (2.5) |
| Capital Expenditure | (0.0) | (0.1) | 0 | 0 | 0 | 0 |
| Free Cash Flow | (142.4) | (166.4) | (81.2) | (29.2) | (14.6) | (2.5) |